The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The accumulation of pathological protein deposits, amyloids, in neurodegenerative disease represents a formidable challenge for drug development. With no effective treatment in sight, and recent findings suggesting that protein aggregates are diverse, dynamic, and capable of spreading, it is crucial that researchers find safe and successful therapeutic approaches that target the most toxic amyloid species. The pathological aggregation of microtubule-associated protein tau has been identified as a critical factor in the progression of Alzheimer's disease and other neurodegenerative disorders. More evidence continues to come to light to suggest that soluble, intermediate tau aggregates-tau oligomers-are the most toxic species in disease and may be responsible for the spread of pathology, rather than neurofibrillary tangles, the primary tauopathy hallmark, suggesting that oligomeric tau may be the best therapeutic target. Here we discuss the potential of small molecules in preventing amyloid and tau oligomer toxicity and future directions.

Original languageEnglish (US)
Title of host publicationNeuroprotection in Alzheimer's Disease
PublisherElsevier Inc.
Pages97-121
Number of pages25
ISBN (Electronic)9780128037126
ISBN (Print)9780128036907
DOIs
StatePublished - Jan 20 2017

Fingerprint

Poisons
Amyloid
Neurodegenerative Diseases
Tauopathies
Amyloidogenic Proteins
Neurofibrillary Tangles
Microtubule-Associated Proteins
Amyloid Plaques
Alzheimer Disease
Research Personnel
Pathology
Therapeutics
Pharmaceutical Preparations
Direction compound
Protein Aggregates

Keywords

  • Amyloid
  • Pathological tau
  • Small molecules
  • Tau aggregation
  • Tau oligomers

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity. / Gerson, J. E.; Lo Cascio, Filippa; Kayed, Rakez.

Neuroprotection in Alzheimer's Disease. Elsevier Inc., 2017. p. 97-121.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gerson, J. E. ; Lo Cascio, Filippa ; Kayed, Rakez. / The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity. Neuroprotection in Alzheimer's Disease. Elsevier Inc., 2017. pp. 97-121
@inbook{d28248ce054b444f92144ef14a7156e7,
title = "The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity",
abstract = "The accumulation of pathological protein deposits, amyloids, in neurodegenerative disease represents a formidable challenge for drug development. With no effective treatment in sight, and recent findings suggesting that protein aggregates are diverse, dynamic, and capable of spreading, it is crucial that researchers find safe and successful therapeutic approaches that target the most toxic amyloid species. The pathological aggregation of microtubule-associated protein tau has been identified as a critical factor in the progression of Alzheimer's disease and other neurodegenerative disorders. More evidence continues to come to light to suggest that soluble, intermediate tau aggregates-tau oligomers-are the most toxic species in disease and may be responsible for the spread of pathology, rather than neurofibrillary tangles, the primary tauopathy hallmark, suggesting that oligomeric tau may be the best therapeutic target. Here we discuss the potential of small molecules in preventing amyloid and tau oligomer toxicity and future directions.",
keywords = "Amyloid, Pathological tau, Small molecules, Tau aggregation, Tau oligomers",
author = "Gerson, {J. E.} and {Lo Cascio}, Filippa and Rakez Kayed",
year = "2017",
month = "1",
day = "20",
doi = "10.1016/B978-0-12-803690-7.00006-5",
language = "English (US)",
isbn = "9780128036907",
pages = "97--121",
booktitle = "Neuroprotection in Alzheimer's Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity

AU - Gerson, J. E.

AU - Lo Cascio, Filippa

AU - Kayed, Rakez

PY - 2017/1/20

Y1 - 2017/1/20

N2 - The accumulation of pathological protein deposits, amyloids, in neurodegenerative disease represents a formidable challenge for drug development. With no effective treatment in sight, and recent findings suggesting that protein aggregates are diverse, dynamic, and capable of spreading, it is crucial that researchers find safe and successful therapeutic approaches that target the most toxic amyloid species. The pathological aggregation of microtubule-associated protein tau has been identified as a critical factor in the progression of Alzheimer's disease and other neurodegenerative disorders. More evidence continues to come to light to suggest that soluble, intermediate tau aggregates-tau oligomers-are the most toxic species in disease and may be responsible for the spread of pathology, rather than neurofibrillary tangles, the primary tauopathy hallmark, suggesting that oligomeric tau may be the best therapeutic target. Here we discuss the potential of small molecules in preventing amyloid and tau oligomer toxicity and future directions.

AB - The accumulation of pathological protein deposits, amyloids, in neurodegenerative disease represents a formidable challenge for drug development. With no effective treatment in sight, and recent findings suggesting that protein aggregates are diverse, dynamic, and capable of spreading, it is crucial that researchers find safe and successful therapeutic approaches that target the most toxic amyloid species. The pathological aggregation of microtubule-associated protein tau has been identified as a critical factor in the progression of Alzheimer's disease and other neurodegenerative disorders. More evidence continues to come to light to suggest that soluble, intermediate tau aggregates-tau oligomers-are the most toxic species in disease and may be responsible for the spread of pathology, rather than neurofibrillary tangles, the primary tauopathy hallmark, suggesting that oligomeric tau may be the best therapeutic target. Here we discuss the potential of small molecules in preventing amyloid and tau oligomer toxicity and future directions.

KW - Amyloid

KW - Pathological tau

KW - Small molecules

KW - Tau aggregation

KW - Tau oligomers

UR - http://www.scopus.com/inward/record.url?scp=85021999777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021999777&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803690-7.00006-5

DO - 10.1016/B978-0-12-803690-7.00006-5

M3 - Chapter

SN - 9780128036907

SP - 97

EP - 121

BT - Neuroprotection in Alzheimer's Disease

PB - Elsevier Inc.

ER -